Plasma Anti thrombin III (AT III) has been measured by Mancini method and serum anti thrombin (AT) activity by Von Kaulla's method in 49 patients treated with intravenous (10 cases) or subcutaneous (39 cases) heparin at therapeutical doses. Among the 39 subcutaneous treated patients, 19 were re-examined after cessation of heparin.A statistically significant decrease in plasma AT III and in serum AT activity has been observed in both groups of heparin-treated patients. In addition, in the 19 subcutaneous treated patients, the plasma AT III and serum AT activity which were decreased under treatment, increased within normal limits after cessation of the treatment : consequently, a congenital AT III deficiency could be ruled out in these patientsIn conclusion, we did find a statistically significant decrease in plasma AT III and in serum AT activity in heparin-treated patients, whatever the route of administration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations鈥揷itations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.